Stockscreener 앱 받기
2.10
7.89%
-0.18
시장 영업 전:
2.09
-0.01
-0.48%
전일 마감가:
$2.28
열려 있는:
$2.26
하루 거래량:
323.75K
Relative Volume:
1.00
시가총액:
$34.13M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.3395
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
-9.87%
1개월 성능:
-15.66%
6개월 성능:
-61.18%
1년 성능:
-90.13%
1일 변동 폭
$2.05
$2.2644
1주일 범위
$2.05
$2.52
52주 변동 폭
$2.05
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.10 | 63.67M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Jasper Therapeutics Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
JSPR SEC FilingsJasper Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Jasper Therapeutics, Inc. (JSPR), Quanex Building Products Corporation (NX), and RCI Hospitality Holdings, Inc. (RICK) - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria - MSN
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Sahm
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options - Lelezard
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain OfficersJSPR - Lelezard
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
Boston Herald - FinancialContent
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications - TipRanks
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Lelezard
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Is Jasper Therapeutics Inc Equity Warrant a good long term investmentMarket Rumors and News & Minimal Investment Trading Tips - earlytimes.in
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics ... - Bluefield Daily Telegraph
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Lelezard
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR - FinancialContent
JSPR Stockholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics ... - Black Hills Pioneer
What analysts say about Jasper Therapeutics Inc Equity Warrant stockMarket Profile Overview & Budget Friendly Trading Alerts - earlytimes.in
Can Jasper Therapeutics Inc. stock weather global recessionMonthly Report 2025 & Develop Consistency in Trading Habits - nchmf.gov.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR Investors Should Contact Robbins LLP Regarding the - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
What analysts say about Jasper Therapeutics Inc stockEconomic Indicators Overview & Explore Stocks for Free with Our Research Portal - earlytimes.in
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):